About Linnaeus Therapeutics
Linnaeus Therapeutics is a private company based in Haddonfield, New Jersey. It has reported $23,844,064 raised in seven offerings on Form D since September 2018. Its chief executive is Patrick Mooney.
Funding Rounds (SEC Form D)
| First sale | Filed with SEC | Amount sold | Investors | Avg. check | Terms | Filing |
|---|---|---|---|---|---|---|
| Feb 17, 2026 | Feb 27, 2026amended Apr 2, 2026 | $4,992,000of $10.0M target | 26 | $192K | EquityRule 506(b) | Form D/A ↗3 earlier filings |
| Aug 19, 2025 | Aug 22, 2025 | $1,275,000of $10.0M target | 3 | $425K | Debt, Securities on exerciseRule 506(c) | Form D ↗ |
| Aug 12, 2024 | Aug 12, 2024amended Dec 26, 2024 | $5,824,155of $6.8M target | 12 | $485K | EquityRule 506(b), 4a5 | Form D/A ↗1 earlier filing |
| Jan 24, 2023 | Jan 26, 2023 | $3,088,234fully sold | 8 | $386K | EquityRule 506(b), 4a5 | Form D ↗ |
| Aug 9, 2021 | Aug 24, 2021 | $4,344,675fully sold | 15 | $289K | EquityRule 506(b), 4a5 | Form D ↗ |
| Jan 23, 2019 | Feb 8, 2019 | $2,160,000target not set | 3 | $720K | EquityRule 506(b), 4a5 | Form D ↗ |
| Aug 27, 2018 | Sep 7, 2018 | $2,160,000target not set | 4 | $540K | EquityRule 506(b), 4a5 | Form D ↗ |
| Total, seven offerings | $23,844,064 | |||||
First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.
Leadership Team
Executive officers and directors listed on Linnaeus Therapeutics's Form D filed Apr 2, 2026.
Earlier filings also listed Jack Lepping (director, last listed Aug 2025), Nicholas Iatropoulos (director, last listed Jan 2023) and Christopher Natale (executive officer, last listed Feb 2019).
Sources
- SECLinnaeus Therapeutics, Inc. Form D/A, filed Mar 31, 2026
- SECLinnaeus Therapeutics, Inc. Form D/A, filed Mar 13, 2026
- SECLinnaeus Therapeutics, Inc. Form D, filed Feb 27, 2026
- SECLinnaeus Therapeutics, Inc. Form D, filed Aug 12, 2024
- SECLinnaeus Therapeutics, Inc. filing history
- InvestorKairos Ventures portfolio page
- PressLinnaeus Therapeutics cancer research award announcement